Global Parathyroid Disease Treatment Market Expansion at 7% CAGR, Valued at $3.10 Billion by 2029

Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.

What Are the Parathyroid Disease Treatment Market Size Forecast for 2025?
The market size for treating parathyroid diseases has been on a steady rise in past years. Projected figures suggest it will expand from $2.21 billion in 2024 to $2.37 billion in 2025, coinciding with a compound annual growth rate (CAGR) of 7.2%. Factors that can account for the growth during the historic period include the heightened occurrence of chronic kidney disease, increased instances of osteoporosis, rising consciousness about endocrine disorders, the broadening scope of diagnostic capabilities, and improved access to specialized healthcare.

What Is the Market Size Outlook for Parathyroid Disease Treatment Until 2029?
Over the upcoming years, the market size of parathyroid disease treatment is anticipated to witness significant growth, expanding to $3.10 billion in 2029 with a compound annual growth rate (CAGR) of 7.0%. Multiple factors such as an escalating geriatric population, growing preference for non-surgical remedies, rising occurrence of bone disorders after menopause, initiatives undertaken by the government for the management of rare diseases, and an increased uptake of minimally invasive parathyroidectomy procedures, contribute to the projected growth during the forecast period. Future trends expected to play a major role in this market include a shift towards personalized hormone therapies, development of long-lasting hormone analogs, application of AI in endocrine diagnosis, focus on drugs targeted at calcium-sensing receptors, and advancements in parathyroid hormone analogs.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/parathyroid-disease-treatment-global-market-report

What Are the Major Factors Driving Demand in the Parathyroid Disease Treatment Market?
An increase in cases of chronic kidney disease (CKD) is expected to positively influence the parathyroid disease treatment market's growth. CKD is a lasting condition in which the kidneys lose their functionality slowly, causing imbalances in minerals like calcium and phosphorus. The surge in CKD cases is largely attributed to the rising prevalence of diabetes, as high blood sugar levels can erode the kidneys' filtering units over time, leading to diabetic nephropathy. Treatment for parathyroid disease plays a fundamental role in managing CKD by addressing secondary hyperparathyroidism, a common complication in advanced CKD stages that disrupts calcium and phosphorus balance, facilitates bone disease, and encourages vascular calcification. For instance, the Australian Institute of Health and Welfare reported that CKD death rates went up by 4.2% in 2021 and 6.2% in 2022. Additionally, CKD was responsible for roughly 22,000 deaths or 11% of total deaths in 2022 in Australia, with a mortality ratio of 84 per 100,000 people. As a result, the burgeoning prevalence of chronic kidney disease is fuelling the expansion of the parathyroid disease treatment market.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25866&type=smp

How Are End-Use Segments Shaping the Parathyroid Disease Treatment Market Outlook?
The parathyroid disease treatment market covered in this report is segmented -

1) By Treatment: Calcimimetics, Bisphosphonates, Plicamycin, Hormone Replacement Therapy, Other Treatments
2) By Route Of Administration: Oral, Parenteral
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users

Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Bisphosphonates: Alendronate, Ibandronate, Risedronate, Zoledronic Acid
3) By Plicamycin: Mithramycin (Plicamycin) Monotherapy, Combination Therapies Involving Plicamycin
4) By Hormone Replacement Therapy: Estrogen Therapy, Progesterone Therapy, Combined Hormonal Therapies, Selective Estrogen Receptor Modulators (SERMs)
5) By Other Treatments: Parathyroid Hormone (PTH) Analogues, Surgery (Parathyroidectomy), Dietary Supplements, Lifestyle And Nutritional Interventions

What Are the Strategic Trends Transforming the Parathyroid Disease Treatment Market Landscape?
Leading firms in the parathyroid disease treatment market are concentrating on the creation of novel products such as parathyroid hormone prodrugs to enhance calcium management and lessen the frequency of doses in hypoparathyroidism patients. These prodrugs of parathyroid hormone (PTH) are dormant compounds that transform into active PTH to maintain the balance of calcium and phosphates in the body. For example, in August 2024, Ascendis Pharma A/S, a biopharmaceutical company from Denmark, earned approval from the US Food and Drug Administration for their product, YORVIPATH (palopegteriparatide), a prodrug of parathyroid hormone for treating chronic hypoparathyroidism in adults. This daily therapy offers continuous exposure to parathyroid hormone for 24 hours, presenting an alternative to traditional calcium and vitamin D supplementation by tackling the core hormone deficiency directly. The affirmation of YORVIPATH highlights the growing interest in advanced hormone replacement therapies with an aim to increase treatment adherence and provide improved clinical results for parathyroid disorder patients.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25866&type=smp

Who Are the Prominent Companies in the Parathyroid Disease Treatment Market by ?
Major companies operating in the parathyroid disease treatment market are AstraZeneca PLC, Amgen Inc., Teijin Pharma Limited, Kyowa Kirin Co. Ltd., Shandong Buchang Pharmaceuticals Co. Ltd., OPKO Health Inc., Septerna Inc., Entera Bio Ltd., Visen Pharmaceuticals (Shanghai) Co. Ltd., Ascendis Pharma A/S, Aeterna Zentaris Inc., MBX Biosciences Inc., STERIS Healthcare Private Limited (subsidiary of STERIS plc), Crinetics Pharmaceuticals Inc., Amorphical Ltd., Vidasym Inc., Extend Biosciences Inc., Rani Therapeutics LLC, Pathalys Pharma Inc., ProLynx LLC.

Which Region Is Expected to See the Highest CAGR in the Parathyroid Disease Treatment Market?
Asia-Pacific was the largest region in the parathyroid disease treatment market in 2024. The regions covered in the parathyroid disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.